sildenafil · Revatio

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pulmonary Arterial Hypertension

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Pediatric Patients (1 to 17 Years Old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise [see Clinical Studies (14) ] . Adults REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clin
Product first approved 2005Outside this platform's coverageFDA label
CA
  • REVATIO (sildenafil citrate) is indicated for: • treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilised on background epoprostenol therapy. REVATIO solution is indicated for: • the continued treatment of patients with pulmonary arterial hypertension (PAH) who are currently...
Product first approved 2006Health Canada
EU
  • Treatment of adult patients with pulmonary arterial hypertension classified as World Health Organization (WHO) functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. Paediatric population Treatment of paediatric patients aged one year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with...
Product first approved 2005EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (61)
Pulmonary Arterial Hypertension
NCT04039464 · Johns Hopkins University
2022-08-01 – 2025-12-31 · Pediatric Pulmonary Hypertension
What this study did
NCT01392469 · Novartis Pharmaceuticals
2011-04-20 – 2012-10-25 · Pulmonary Arterial Hypertension
What this study did
NCT00586794 · Competence Network for Congenital Heart Defects
2007-12 – 2012-06 · Pulmonary Arterial Hypertension (PAH)
What this study did
NCT00795639 · Pfizer
2008-12 – 2011-03 · Pulmonary Arterial Hypertension, Pulmonary Hypertension
What this study did
NCT00796510 · Pfizer
2010-07 – 2011-01 · Pulmonary Arterial Hypertension, Pulmonary Hypertension
What this study did
NCT00780728 · University Health Network, Toronto
— · Hypertension, Pulmonary
What this study did
NCT00454207 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-04 – 2009-02 · Pulmonary Hypertension
What this study did
NCT00302211 · Actelion
2006-02-01 – 2008-07-01 · Pulmonary Hypertension
What this study did
Other / comorbidity
NCT06123156 · University Hospital, Rouen
2025-09-25 – 2030-02 · Rectal Cancer
What this study did
NCT06377098 · University of Alabama at Birmingham
2025-05-01 – 2028-09-30 · Neonatal Asphyxia, Intrapartum Fetal Distress, Development, Infant, Intrapartum Asphyxia
What this study did
NCT03997097 · University Hospital, Montpellier
2023-06-01 – 2028-06-01 · Single-ventricle, Pulmonary Hypertension, Univentricular Heart
What this study did
NCT06522854 · University of Alabama at Birmingham
2025-05-01 – 2026-11-30 · Intrapartum Fetal Distress, Neonatal Asphyxia, Intrapartum Asphyxia, Instrumental Delivery; Affecting Fetus
What this study did
NCT05490680 · IBSA Institut Biochimique SA
2024-01-26 – 2024-12-09 · Erectile Dysfunction
What this study did
NCT05584956 · Tanta University
2022-07-08 – 2024-07-08 · Beta Thalassemia With Increased Tricuspid Regurgitant Jet Velocity
What this study did
NCT04052269 · Imperial College London
2019-06-21 – 2022-10-30 · Glaucoma
What this study did
NCT02930811 · University Hospital, Angers
est. completion 2022-10 · Peripheral Arterial Occlusive Disease
What this study did
NCT03406169 · Brooke Army Medical Center
2017-02-13 – 2022-03 · Erectile Dysfunction, Prostate Cancer
What this study did
NCT03356353 · University of Calgary
2018-03-12 – 2022-01 · End Stage Heart Failure
What this study did
NCT04304313 · Tongji Hospital
2020-02-09 – 2020-11-09 · COVID-19
What this study did
NCT01720524 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2013-08-05 – 2020-09-28 · Pulmonary Hypertension, Familial Persistent, of the Newborn
What this study did
NCT01616381 · Helse Stavanger HF
2013-03 – 2019-12 · Heart Failure, Pulmonary Hypertension
What this study did
NCT03154476 · Mayo Clinic
2017-07-05 – 2019-06-30 · Cirrhosis, Congenital Heart Disease
What this study did
NCT01913847 · Hanmi Pharmaceutical Company Limited
2013-09 – 2018-12 · Pulmonary Hypertension, Systolic Dysfunction
What this study did
NCT03460470 · Hartford Hospital
2018-02-14 – 2018-12 · Heart Failure, Pulmonary Hypertension
What this study did
NCT03230162 · Ain Shams University
2017-06-01 – 2018-05-01 · Fetal Growth Abnormality, Fetal Growth Restriction
What this study did
NCT03177824 · Ain Shams University
2017-03-30 – 2017-10-01 · Fetal Growth Restriction
What this study did
NCT02832570 · University Hospital, Angers
2016-11-07 – 2017-10 · Peripheral Arterial Occlusive Disease
What this study did
NCT02590536 · Ain Shams University
2015-10 – 2017-06-02 · Fetal Growth Retardation
What this study did
NCT02850718 · iX Biopharma Ltd.
2016-03 – 2016-05 · Erectile Dysfunction
What this study did
NCT01558466 · Hamad Medical Corporation
2011-11 – 2015-06 · Persistent Fetal Circulation Syndrome
What this study did
NCT01726049 · University Medical Center Groningen
2011-10 – 2014-12 · Heart Failure, Diastolic, Pulmonary Hypertension
What this study did
NCT00142506 · Memorial Sloan Kettering Cancer Center
2005-02 – 2014-04 · Prostate Cancer, Erectile Dysfunction
What this study did
NCT01295736 · University Hospital, Lille
2010-11 – 2013-08 · Systemic Scleroderma
What this study did
NCT01091012 · Hospital Universitari Vall d'Hebron Research Institute
2011-09 – 2013-02 · Pulmonary Hypertension
What this study did
NCT01441934 · Italian Association of Hospital Pneumologists
2010-10 – 2013-02 · Pulmonary Hypertension, COPD
What this study did
NCT01347008 · Federal University of São Paulo
2011-04 – 2013-01 · Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma, Limited, Raynaud Phenomenon
What this study did
NCT01315262 · Università Vita-Salute San Raffaele
2011-01 – 2012-12 · Erectile Dysfunction
What this study did
NCT00431418 · Mercy Hospital for Women, Australia
2007-01 – 2012-06 · Lung Diseases
What this study did
NCT00544076 · City of Hope Medical Center
2006-01 – 2012-04 · Prostate Cancer, Male Erectile Disorder, Stage I Prostate Cancer, Stage II Prostate Cancer
What this study did
NCT00742014 · The Hospital for Sick Children
2008-08 – 2011-08 · Hypertension
What this study did
NCT00454714 · Udo Sechtem
2007-03-01 – 2009-12-31 · Coronary Vasospasm
What this study did
Phase 2/3 (23)
Pulmonary Arterial Hypertension
NCT07824674 · Silvia Ulrich
2026-10-26 – 2028-12 · Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
What this study did
NCT01637675 · The First Affiliated Hospital of Guangzhou Medical University
2013-05 – 2014-12 · Pulmonary Hypertension, Pulmonary Arterial Hypertension, Cardiovascular Diseases, Lung Diseases, Tanshinone IIA Sulfonate
What this study did
Other / comorbidity
NCT06800092 · The University of Texas Medical Branch, Galveston
2027-06-15 – 2030-06-01 · Cancer
What this study did
NCT07462260 · Sindh Institute of Cardiovascular Diseases
2025-08-01 – 2026-09-23 · Pulmonary Hypertension, Rheumatic Valvular Heart Disease
What this study did
NCT04039087 · National Jewish Health
2019-09-05 – 2024-06-30 · Cystic Fibrosis
What this study did
NCT05971667 · Beni-Suef University
2023-07-30 – 2023-10-30 · IVF
What this study did
NCT05951413 · Beni-Suef University
2023-06-30 – 2023-09-30 · IVF
What this study did
NCT05846906 · Beni-Suef University
2021-10-01 – 2022-04-30 · Infertility, Female
What this study did
NCT02442492 · University of British Columbia
2017-01 – 2019-04 · Intrauterine Growth Restriction (IUGR), Fetal Growth Restriction (FGR)
What this study did
NCT03763045 · Ain Shams University
2018-12-02 – 2019-02-28 · Pulmonary Hypertension, Hemodialysis Complication
What this study did
NCT02277132 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2015-01 – 2018-07-19 · Fetal Growth Restriction
What this study did
NCT02435303 · Asan Medical Center
2016-05 – 2018-06 · Hypertension, Pulmonary, Diseases of Mitral Valve
What this study did
NCT03262961 · Assiut University
2016-09-15 – 2018-01-15 · Pre-Eclampsia; Mild
What this study did
NCT02782559 · The University of Texas Health Science Center, Houston
2016-07 – 2017-07 · Preterm Preeclampsia
What this study did
NCT00981747 · Alicia Gerke
2009-09 – 2016-12 · Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
What this study did
NCT02766725 · Assiut University
2015-01 – 2015-12 · Infertility
What this study did
NCT02050360 · University Hospital, Grenoble
2013-11 – 2015-05 · Raynaud's Phenomenon
What this study did
NCT01936350 · Hospital Ana Nery
2013-09 – 2013-11 · Heart Failure
What this study did
NCT01107782 · Tehran University of Medical Sciences
2008-06 – 2012-01 · Fetal Growth Retardation
What this study did
NCT00752115 · Hamamatsu University
2007-02 – 2010-12 · Non-small Cell Lung Cancer
What this study did
NCT00872170 · Carelon Research
2009-03 – 2010-11 · Thalassemia, Hypertension, Pulmonary
What this study did
NCT01156636 · University of Milan
2006-01 – 2009-12 · Pulmonary Hypertension, Diastolic Heart Failure
What this study did
Phase 2 (71)
Pulmonary Arterial Hypertension
NCT01517854 · University Health Network, Toronto
2012-11-14 – 2019-05-14 · Portopulmonary Hypertension
What this study did
Other / comorbidity
NCT06098833 · Pia Wintermark
2024-07-01 – 2031-10 · Neonatal Encephalopathy
What this study did
NCT06810284 · Assistance Publique - Hôpitaux de Paris
2026-10 – 2029-05 · Hypoxic-Ischemic Encephalopathy
What this study did
NCT05782244 · University of Pennsylvania
2024-07-02 – 2027-12-31 · Traumatic Brain Injury
What this study did
NCT07647003 · NuSirt Biopharma
2026-10-15 – 2027-07-07 · Hypertension
What this study did
NCT05061368 · University of Alberta
2022-03-01 – 2027-05 · Chronic Obstructive Pulmonary Disease
What this study did
NCT04565925 · The University of Texas Medical Branch, Galveston
2021-07-07 – 2026-12-01 · Spinal Cord Injuries, Urinary Incontinence
What this study did
NCT04797286 · Johns Hopkins University
2021-09-20 – 2026-11-01 · Scleroderma, Mildly Elevated Pulmonary Pressures
What this study did
NCT05201144 · University of Utah
2022-09-15 – 2026-09-30 · Congenital Diaphragmatic Hernia, Pulmonary Hypertension
What this study did
NCT07290400 · Aspargo Labs, Inc
2026-04-15 – 2026-06-28 · Erectile Dysfunction
What this study did
NCT07231185 · Aspargo Labs, Inc
2026-01 – 2026-03 · Erectile Dysfunction
What this study did
NCT07135037 · Kafrelsheikh University
2024-09-01 – 2025-12-31 · Oligohydramnios
What this study did
NCT03142568 · University of North Carolina, Chapel Hill
2018-04-02 – 2025-03-01 · Bronchopulmonary Dysplasia
What this study did
NCT04447989 · Christoph Hornik
2021-05-27 – 2025-01-15 · Bronchopulmonary Dysplasia of Newborn
What this study did
NCT04985929 · University of Alberta
2021-07-01 – 2024-07-05 · Healthy
What this study did
NCT05556083 · Al-Azhar University
2022-10-01 – 2023-11-01 · Premature Ejaculation
What this study did
NCT01817751 · Virginia Commonwealth University
2013-04-11 – 2023-05-12 · Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
What this study did
NCT03855332 · University of Oxford
2019-07-11 – 2023-01-06 · Small Vessel Cerebrovascular Disease
What this study did
NCT04948151 · Strategic Science & Technologies, LLC
2021-06-28 – 2021-12-15 · Female Sexual Arousal Disorder
What this study did
NCT03686813 · Duke University
2019-07-15 – 2021-10-29 · Edema, Pulmonary, Immersion, Diving
What this study did
NCT02335242 · Stanford University
2015-05-23 – 2021-03-30 · Lymphatic Malformations, Lymphatic Diseases
What this study did
NCT02908490 · Kimberly Liang
2017-04-01 – 2020-12-31 · Arthritis, Rheumatoid, Atherosclerosis
What this study did
NCT04058132 · Uniformed Services University of the Health Sciences
2019-08-09 – 2020-03-01 · Traumatic Brain Injury
What this study did
NCT03696758 · University of Wisconsin, Madison
2018-10-30 – 2020-02-24 · Infant,Premature
What this study did
NCT04356716 · Columbia University
2014-11-11 – 2020-02-18 · Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
What this study did
NCT04718233 · Ain Shams University
2018-09-05 – 2019-07-01 · Recurrent Pregnancy Loss
What this study did
NCT03598140 · University of Texas Southwestern Medical Center
2018-07-25 – 2019-05-29 · Vascular System Injuries, Concussion, Brain, Post-Concussion Syndrome
What this study did
NCT02057458 · Augusta University
2014-04 – 2018-07 · Cystic Fibrosis
What this study did
NCT02570282 · Strategic Science & Technologies, LLC
2015-09 – 2017-07 · Sexual Arousal Disorder
What this study did
NCT02390960 · Strategic Science & Technologies, LLC
2015-03 – 2017-06 · Erectile Dysfunction
What this study did
NCT01132482 · National Jewish Health
2015-10 – 2017-05 · Cystic Fibrosis
What this study did
NCT02678221 · Assiut University
2016-02 – 2017-04 · Intrauterine Growth Restriction
What this study did
NCT02663830 · Ain Shams University
2016-01-10 – 2017-03-12 · Anovulatory
What this study did
NCT02244528 · Seoul National University Hospital
2014-10 – 2016-10 · Neonates and Preterm Infants
What this study did
NCT02571101 · CTC Bio, Inc.
2015-11 – 2016-06 · Premature Ejaculation
What this study did
NCT02845388 · Omar Ahmed El Sayed Saad
2015-09 – 2016-06 · Infertility
What this study did
NCT01762475 · Uniformed Services University of the Health Sciences
2013-01 – 2015-12 · Traumatic Brain Injury, Post-concussive Syndrome
What this study did
NCT01830790 · Duke University
2013-03 – 2014-05 · Age-related Macular Degeneration
What this study did
NCT01168908 · Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
2010-09 – 2014-01 · Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
What this study did
NCT01481350 · University of Turin, Italy
2012-02 – 2013-12 · Pulmonary Hypertension
What this study did
NCT00940901 · Johns Hopkins University
2008-06 – 2013-12 · Sickle Cell Disease, Priapism
What this study did
NCT01409031 · University of Colorado, Denver
2011-07 – 2013-10 · Persistent Pulmonary Hypertension, Respiratory Failure
What this study did
NCT01432665 · Emotional Brain NY Inc.
2011-09 – 2013-05 · Hypoactive Sexual Desire Disorder
What this study did
NCT01179334 · Bayer
2010-08 – 2013-05 · Pulmonary Hypertension
What this study did
NCT01360671 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2012-03 – 2013-04 · Persistent Pulmonary Hypertension of the Newborn
What this study did
NCT01350154 · Copenhagen University Hospital, Rigshospitalet
2011-11 – 2013-04 · Becker Muscular Dystrophy
What this study did
NCT01601470 · Novartis Pharmaceuticals
2012-09 – 2013-01 · Mild to Moderate Hypertension
What this study did
NCT01091870 · Hospital de Clinicas de Porto Alegre
2010-03 – 2012-12 · Subarachnoid Hemorrhage, Cerebral Vasospasm, Rupture of Intracranial Aneurysm
What this study did
NCT01069861 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-12 – 2011-11 · PPHN, Persistent Pulmonary Hypertension of the Newborn, Hypoxic Respiratory Failure
What this study did
Phase 1/2 (14)
Other / comorbidity
NCT03012386 · Vanderbilt University Medical Center
2017-01 – 2021-07-31 · Insulin Resistance, Endothelial Dysfunction
What this study did
NCT04489446 · Universidad Nacional Andres Bello
2020-08-19 – 2021-06-30 · Covid19, SARS-COV2 Infection
What this study did
NCT04100759 · Ain Shams University
2019-06-11 – 2019-07-08 · Erectile Dysfunction, Smoking, Pharmacokinetics, Pharmacodynamics
What this study did
NCT03259516 · St. Petersburg State Pavlov Medical University
2017-05-25 – 2018-12-25 · Myelodysplastic Syndromes
What this study did
NCT02626182 · National Jewish Health
2015-12 – 2018-01-29 · Cystic Fibrosis
What this study did
NCT03192709 · Royan Institute
2015-02 – 2017-09 · Infertility, Female
What this study did
NCT02595541 · Assiut University
2015-06 – 2015-10 · Pulmonary Hypertension
What this study did
NCT01853540 · National Institute of Allergy and Infectious Diseases (NIAID)
2013-01 – 2014-10 · Nontuberculous Mycobacterial Infection
What this study did
NCT02028429 · Post Graduate Institute of Medical Education and Research, Chandigarh
2012-07 – 2014-01 · Hepatic Encephalopathy.
What this study did
NCT01290484 · Stanford University
2010-12 – 2013-12 · Lymphangioma
What this study did
NCT01334554 · Vanderbilt University Medical Center
2011-04 – 2013-08 · Metabolic Syndrome, Obesity
What this study did
NCT01194232 · Children's Hospital Medical Center, Cincinnati
2012-08 – 2012-12 · Cystic Fibrosis With Mild to Moderate Lung Disease, CMRI of Lung Perfusion, Lung Perfusion, Lung Vascularization
What this study did
NCT00659529 · National Jewish Health
2008-08 – 2012-12 · Cystic Fibrosis
What this study did
NCT00123162 · Milton S. Hershey Medical Center
2007-05 – 2011-08 · Dysmenorrhea
What this study did
Phase 1 (77)
Pulmonary Arterial Hypertension
NCT04994860 · Bial - Portela C S.A.
2018-03-22 – 2018-06-07 · Pulmonary Arterial Hypertension
What this study did
NCT01244620 · Pfizer
2010-11 – 2010-12 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT06510322 · Montefiore Medical Center
2025-03-12 – 2029-12 · Vascular Diseases
What this study did
NCT02983461 · The University of Texas Medical Branch, Galveston
2017-03-10 – 2028-07 · Urinary Incontinence
What this study did
NCT07039760 · Washington University School of Medicine
2026-10-31 – 2028-05-31 · Brain Tumor
What this study did
NCT06324396 · Children's Mercy Hospital Kansas City
2024-03-01 – 2027-12-31 · Fontan Circulation
What this study did
NCT07508358 · Kevin Hellman
2026-10-01 – 2027-07 · Dysmenorrhea, Menstrual Pain, Endometriosis, Uterine Fibroid
What this study did
NCT07302698 · Aspargo Labs, Inc
2026-03-15 – 2026-05-28 · Healthy Volunteers
What this study did
NCT06839651 · Universitas Indonesia
2025-04-21 – 2026-04-01 · Erectile Dysfunctions
What this study did
NCT07117383 · Aspargo Labs, Inc
2026-01 – 2026-03 · Erectile Dysfunction
What this study did
NCT04169191 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2019-09-19 – 2025-10-31 · Birth Asphyxia
What this study did
NCT06289881 · Bio-innova Co., Ltd
2025-02-04 – 2025-03-25 · Healthy Subjects
What this study did
NCT06782659 · Aspargo Labs, Inc
2025-01 – 2025-03 · Erectile Dysfunction
What this study did
NCT05275725 · Pia Wintermark
2022-07-01 – 2025-01-31 · Birth Asphyxia
What this study did
NCT05765487 · Daré Bioscience, Inc.
2023-05-13 – 2024-10-21 · Sexual Arousal Disorder
What this study did
NCT05466695 · Assiut University
2022-08-01 – 2023-08-01 · Erectile Dysfunction and Neutrophil Lymphocyte Ratio
What this study did
NCT03945643 · University of Oregon
2019-07-01 – 2023-07-31 · Patent Foramen Ovale, Intrapulmonary Arteriovenous Anastamosis
What this study did
NCT03028298 · University of Mississippi Medical Center
2016-12 – 2023-07 · Subarachnoid Hemorrhage, Cerebral Vasospasm
What this study did
NCT06565728 · Cairo University
2022-11-03 – 2023-05-06 · Fetal Growth Retardation
What this study did
NCT05684289 · Bristol-Myers Squibb
2023-01-03 – 2023-05-02 · Healthy Participants
What this study did
NCT03199612 · Montefiore Medical Center
2019-06-03 – 2023-01-20 · Thrombosis, Hemolysis
What this study did
NCT06527729 · Assiut University
2021-07-01 – 2022-10-01 · Alopecia Areata
What this study did
NCT03417492 · University of Pennsylvania
2018-03-01 – 2022-06-30 · Traumatic Brain Injury, Mild Traumatic Brain Injury, Post-Concussion Syndrome
What this study did
NCT04283435 · Cairo University
2021-09-01 – 2022-03-01 · IVF, Endometrial Receptivity
What this study did
NCT02812433 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2016-07 – 2022-01 · Neonatal Encephalopathy
What this study did
NCT04770155 · University of Mississippi Medical Center
2021-05-27 – 2021-09-20 · Vascular Function, Racial Disparity
What this study did
NCT02795351 · Herlev Hospital
2015-06 – 2021-08 · Migraine With Aura
What this study did
NCT04882826 · Pharmtechnology LLC
2021-05-10 – 2021-05-30 · Bioequivalence
What this study did
NCT04391868 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2021-01-30 – 2021-04-28 · Healthy
What this study did
NCT04211272 · Actelion
2020-01-14 – 2021-04-19 · Healthy
What this study did
NCT02946944 · Meshalkin Research Institute of Pathology of Circulation
2016-10 – 2020-10 · Pulmonary Embolism, Intermediate-high Risk, Combination of Oral Anticoagulation Therapy and Sildenafil
What this study did
NCT03229512 · Northwestern University
2017-04-11 – 2020-06-04 · Hand Foot Skin Reaction
What this study did
NCT02466802 · Virginia Commonwealth University
2015-07-01 – 2019-01-28 · Solid Tumor
What this study did
NCT04481789 · Shionogi
2018-10-17 – 2019-01-08 · Healthy Adult Subjects
What this study did
NCT03766594 · Ain Shams University
2018-01-01 – 2018-12-01 · Miscarriage, Recurrent
What this study did
NCT04283240 · University of Aarhus
2015-03-01 – 2018-09-10 · Pulmonary Embolism
What this study did
NCT03510338 · N4 Pharma UK Ltd.
2018-05-08 – 2018-06-13 · Erectile Dysfunction
What this study did
NCT03755037 · Nesreen Abdel Fattah Abdullah Shehata
2017-01-31 – 2018-04-30 · Female Infertility
What this study did
NCT01375699 · Virginia Commonwealth University
2011-08-11 – 2018-01-19 · Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Sarcoma, Gynecologic Cancer
What this study did
NCT02114775 · The University of Texas Medical Branch, Galveston
2014-12-12 – 2017-11-10 · Traumatic Brain Injury
What this study did
NCT02975037 · Seoul National University Hospital
2017-02-06 – 2017-06-23 · Healthy
What this study did
NCT02106871 · The University of Texas Medical Branch, Galveston
2014-04 – 2017-06 · Pancreatic Cancer, Cholangiocarcinoma
What this study did
NCT00223717 · Vanderbilt University
2001-01 – 2017-01 · Hypertension
What this study did
NCT02337881 · Al Hayat National Hospital
2015-01 – 2016-10 · Labor Preterm Requiring Hospitalization
What this study did
NCT02628847 · University of Utah
2012-03 – 2016-10 · Stroke
What this study did
NCT01670136 · University of North Carolina, Chapel Hill
2013-02 – 2016-07 · Persistent Pulmonary Hypertension of the Newborn
What this study did
NCT01950923 · Wake Forest University Health Sciences
2013-09 – 2016-03 · Kidney Tumor
What this study did
NCT00815646 · Duke University
2008-01 – 2015-12 · Immersion Pulmonary Edema (IPE), Swimming Induced Pulmonary Edema (SIPE)
What this study did
NCT01954524 · University of Maryland, Baltimore
2014-05 – 2015-10 · Cirrhosis
What this study did
Phase 4 (97)
Pulmonary Arterial Hypertension
NCT01642407 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2012-08-24 – 2018-03-12 · Pulmonary Arterial Hypertension, Hypertension, Pulmonary
What this study did
NCT03053739 · Post Graduate Institute of Medical Education and Research, Chandigarh
2016-12 – 2017-12 · Associated Pulmonary Arterial Hypertension
What this study did
NCT03236818 · Amsterdam UMC, location VUmc
2013-05 – 2017-09 · Pulmonary Arterial Hypertension
What this study did
NCT00433329 · Actelion
2007-03 – 2010-08 · Pulmonary Arterial Hypertension
What this study did
NCT00430716 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-04-08 – 2010-05-25 · Pulmonary Arterial Hypertension
What this study did
NCT00625079 · University of California, Los Angeles
2007-02 – 2009-12 · Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
What this study did
NCT00483626 · University of Chile
2003-08 – 2007-06 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT06649539 · Charitable Union for the Research and Education of Peyronie's Disease
2024-10-11 – 2029-10 · Peyronie Disease
What this study did
NCT07391579 · Mansoura University
2025-12-01 – 2027-06 · Erectile Dysfunctions
What this study did
NCT07769476 · Nishtar Medical University
2025-07-01 – 2025-12-30 · Polycystic Ovarian Syndrome (PCOS), Polyendocrine Metabolic Ovarian Syndrome (PMOS)
What this study did
NCT02682147 · Eric A. Hoffman
2017-07-10 – 2025-05 · Emphysema
What this study did
NCT06178523 · Batterjee Medical College
2024-01-01 – 2024-12-31 · Unexplained Infertility
What this study did
NCT03382106 · Eric A. Hoffman
2018-03-19 – 2024-09-24 · Emphysema
What this study did
NCT04538976 · Chronic Obstructive Pulmonary Disease Trial Network, Denmark
2020-02-01 – 2024-03-15 · Acute Exacerbation of COPD
What this study did
NCT04908657 · National Taiwan University Hospital
2017-07-03 – 2023-12-31 · Liver Fibrosis
What this study did
NCT03402191 · Sherief Abd-Elsalam
2016-07 – 2023-12 · Thalassemia
What this study did
NCT05753098 · Beni-Suef University
2021-01-15 – 2023-01-31 · Subfertility, Female
What this study did
NCT05183334 · Assiut University
2021-12-30 – 2022-12-25 · Premature Ejaculation
What this study did
NCT05558176 · Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso
2022-04-08 – 2022-10-31 · Foetal Hypoxia
What this study did
NCT04325243 · Assiut University
2020-09-01 – 2022-07-31 · Fetal Distress
What this study did
NCT00245596 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
started 2005-10 · Impotence
What this study did
NCT00249730 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
started 2005-10 · Impotence
What this study did
NCT00151463 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
started 2005-01 · Impotence
What this study did
NCT00906269 · Hartford Hospital
2009-07 – 2021-01 · Impotence, Prostatic Neoplasms
What this study did
NCT02890238 · Cairo University
2016-08 – 2019-12 · Infertility
What this study did
NCT03169582 · Eduardo Vargas-Baquero
2016-04-01 – 2018-06-01 · Erectile Dysfunction
What this study did
NCT02378649 · Dr. Robert Klempfner Heart Rehabilitation Institute
2015-03 – 2018-06 · Pulmonary Hypertension, Mitral Valve Surgery
What this study did
NCT02620995 · National Institute of Cardiology, Laranjeiras, Brazil
2014-10 – 2018-01 · Arterial Hypertension, Erectile Dysfunction
What this study did
NCT02519153 · Mansoura University
2014-07 – 2017-09 · Ureteral Stone, Urolithiasis
What this study did
NCT03044561 · Ain Shams University
2017-01-31 – 2017-08-10 · IVF Failure
What this study did
NCT02939495 · Neutec Ar-Ge San ve Tic A.Ş
2016-10 – 2017-08 · Premature Ejaculation, Erectile Dysfunction
What this study did
NCT02304705 · Maya Guglin
2015-01 – 2017-06 · Heart Failure With Reactive Pulmonary Hypertension
What this study did
NCT02129725 · Vanderbilt University Medical Center
2014-04 – 2016-12 · Metabolic Syndrome
What this study did
NCT01409993 · Vanderbilt University
2011-08 – 2016-11 · Impaired Glucose Tolerance
What this study did
NCT02345980 · Mansoura University
2014-03 – 2016-11 · Quality of Life
What this study did
NCT02524184 · Xiang Guang-da
2015-08 – 2016-09 · Obesity
What this study did
NCT00862043 · Hospital General Universitario Gregorio Marañon
2009-04 – 2016-07 · Pulmonary Hypertension, Valvular Heart Disease
What this study did
NCT01889966 · Kerckhoff Heart Center
2013-04 – 2015-01 · Pulmonary Hypertension Associated With Connective Tissue Disease
What this study did
NCT01800292 · University of Arizona
2013-02 – 2014-12 · Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
What this study did
NCT01815502 · Medical University of South Carolina
2013-02 – 2014-12 · Single Ventricle Heart Disease After Fontan Surgery
What this study did
NCT03733470 · Eric A. Hoffman
2011-06-29 – 2014-01-13 · Emphysema
What this study did
NCT00133679 · University of California, San Francisco
2006-02 – 2013-10 · Hernia, Diaphragmatic, Hypertension, Pulmonary, Hypoplasia, Pulmonary
What this study did
NCT01382368 · Rabin Medical Center
2011-09 – 2013-09 · Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis
What this study did
NCT01449253 · All India Institute of Medical Sciences
2011-08 – 2013-07 · Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia
What this study did
NCT00730067 · University of Aarhus
2012-06 – 2012-12 · COPD, Pulmonary Hypertension
What this study did
NCT01757782 · Sir Takhtasinhji General Hospital
2011-12 – 2012-09 · Meconium Aspiration Syndrome, Persistent Pulmonary Hypertension of Newborn
What this study did
NCT01364701 · Rambam Health Care Campus
2011-06 – 2012-07 · Erectile Dysfunction
What this study did
NCT01352507 · Eli Lilly and Company
2011-06 – 2012-07 · Erectile Dysfunction
What this study did
Early phase / not applicable (52)
Pulmonary Arterial Hypertension
NCT01548950 · University of Sao Paulo General Hospital
2011-09 – 2020-03 · Congenital Heart Disease, Pulmonary Arterial Hypertension
What this study did
NCT01391104 · Laval University
2009-04 – 2011-11 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT04912726 · Universidad del Norte
2025-01-01 – 2026-12-30 · Hypertension, Pulmonary
What this study did
NCT07293156 · Benha University
2025-12-15 – 2026-11-11 · Diabete Mellitus, Erectile Dysfunction Associated With Type 2 Diabetes Mellitus, Pilates Exercise, Pelvic Floor Muscle Exercise
What this study did
NCT06778330 · Fayoum University
2025-01-20 – 2025-08-01 · Heart Failure NYHA Class II
What this study did
NCT07245875 · Universitas Indonesia
2024-04-12 – 2025-08-01 · Erectile Dysfunction, Diabetes Mellitus Type 2
What this study did
NCT04344678 · Sadat City University
2020-01-01 – 2024-12-31 · Major Depressive Disorder
What this study did
NCT06237751 · First People's Hospital of Chenzhou
2024-02-01 – 2024-12-30 · Central Venous Pressure, Hepatectomy, Hemodynamics Instability, Sildenafil
What this study did
NCT06562036 · Muhammad Aamir Latif
2023-12-01 – 2024-05-31 · Persistent Pulmonary Hypertension of the Newborn
What this study did
NCT05669885 · Danish Headache Center
2023-01-02 – 2023-12-31 · Post-Traumatic Headache
What this study did
NCT05889455 · Danish Headache Center
2023-04-20 – 2023-10-12 · Migraine Without Aura
What this study did
NCT04715113 · University of Zurich
2021-02-01 – 2023-05-31 · Hypertension, Pulmonary
What this study did
NCT04697862 · University of Zurich
2021-02-01 – 2023-05-31 · Hypertension, Pulmonary
What this study did
NCT04704440 · University of Zurich
2021-02-01 – 2023-05-31 · Hypertension, Pulmonary
What this study did
NCT04706546 · University of Zurich
2021-02-01 – 2023-05-31 · Hypertension, Pulmonary
What this study did
NCT04122105 · University of British Columbia
2021-04-01 – 2023-01-01 · Renal Transplant Failure
What this study did
NCT05369481 · Mohammed Abd El Mawgoud Amer
2022-03-01 – 2022-09-01 · Androgenic Alopecia
What this study did
NCT03724838 · Aswan University Hospital
2018-12-01 – 2022-01-01 · Preeclampsia
What this study did
NCT03185364 · Chinese Academy of Medical Sciences, Fuwai Hospital
2017-06-15 – 2020-12-31 · COPD, Pulmonary Hypertension
What this study did
NCT00955929 · Memorial Sloan Kettering Cancer Center
2009-08-06 – 2020-12-09 · Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
What this study did
NCT04170790 · Ain Shams University
2019-12-01 – 2020-01-30 · Diabetes Mellitus, Type 2, Erectile Dysfunction With Diabetes Mellitus, Drug Interaction
What this study did
NCT03854175 · Cairo University
2019-02 – 2020-01 · Infertility
What this study did
NCT04126252 · International Islamic University, Islamabad
2018-08-29 – 2019-09-03 · Erectile Dysfunction
What this study did
NCT03143465 · Danish Headache Center
2016-08 – 2019-05 · Migraine With Aura
What this study did
NCT03710369 · University of British Columbia
2015-11-01 – 2018-10-02 · Altitude, Hypoxia, Sildenafil, Exercise
What this study did
NCT03301233 · Ain Shams University
2017-11-01 – 2018-07-30 · Endometrial Thickness
What this study did
NCT02414204 · University of Alabama at Birmingham
2015-04 – 2018-06-30 · Improve Endothelial Function and Decrease Vascular Stenosis
What this study did
NCT03153215 · Beni-Suef University
2017-05-06 – 2017-12-31 · Intra-Uterine Growth Retardation
What this study did
NCT03475160 · Benha University
2015-12-01 – 2017-12-01 · Recurrent Abortion
What this study did
NCT01996852 · Case Comprehensive Cancer Center
2013-07 – 2016-08 · Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Simple Prostatectomy, Erectile Dysfunction
What this study did
NCT02372487 · Al Hayat National Hospital
2015-03 – 2016-06 · Pregnancy Complication
What this study did
NCT02362399 · Al Hayat National Hospital
2015-03 – 2016-04 · Pregnancy Complication
What this study did
NCT02710981 · Assiut University
2015-06 – 2016-01 · Anovulation
What this study did
NCT01661595 · The University of Texas Medical Branch, Galveston
2012-11 – 2015-06 · Fatigue
What this study did
NCT01812434 · University of Minnesota
2010-10 – 2015-03 · Cardiac Allograft Vasculopathy
What this study did
NCT01572363 · Universitaire Ziekenhuizen KU Leuven
2012-04 – 2014-03 · Congenital Heart Disease
What this study did
NCT01059994 · The University of Texas Medical Branch, Galveston
2010-01 – 2013-07 · Fatigue, Aging
What this study did
NCT01054001 · Seoul National University Bundang Hospital
2010-06 – 2013-01 · Prostate Cancer
What this study did
NCT00478335 · University of Colorado, Denver
2007-05 – 2012-10 · Nephrogenic Diabetes Insipidus
What this study did
NCT01392638 · University of Campinas, Brazil
2010-07 – 2012-09 · Hypertension
What this study did
NCT01948518 · The Cleveland Clinic
2009-06 – 2012-06 · Diffuse Parenchymal Lung Disease, Pulmonary Hypertension
What this study did
NCT01373749 · Third Military Medical University
2011-03 – 2012-03 · Persistent Pulmonary Hypertension of Newborn
What this study did
NCT00710099 · University Hospital, Grenoble
2008-07 – 2011-06 · Healthy
What this study did
NCT00808912 · Marywood University
2008-12 – 2010-02 · Pulmonary Hypertension, Pulmonary Artery Pressure, Exercise Performance, Air Pollution
What this study did
NCT00463957 · University of Cambridge
started 2006-08 · Erectile Dysfunction
What this study did
NCT00772135 · Oslo University Hospital
2008-09 – 2009-04 · Congenital Heart Disease
What this study did
NCT00685945 · Vanderbilt University
2007-12 – 2009-01 · Obesity
What this study did
NCT00511498 · Johns Hopkins University
2006-03 – 2008-10 · Prostate Cancer
What this study did
NCT00599235 · University of Edinburgh
2007-03 – 2008-08 · Hypertension
What this study did
NCT00057759 · Radiation Therapy Oncology Group
2003-01 – 2006-12 · Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction, Sexuality and Reproductive Issues
What this study did
Used as active comparator (20)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT02802345 · Boehringer Ingelheim
2016-06-30 – 2018-04-13 · Idiopathic Pulmonary Fibrosis
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02798159 · Vietstar Biomedical Research
2016-05 – 2018-07-01 · Erectile Dysfunction
What this study did
Phase 2 (1)
Pulmonary Arterial Hypertension
Phase 1/2 (1)
Other / comorbidity
NCT06860399 · Damascus University
2023-05-01 – 2024-09-30 · PPHN
What this study did
Phase 1 (6)
Other / comorbidity
NCT07732387 · Yanping Kong
2026-08-01 – 2026-09-19 · Erectile Dysfunctions, Healthy Volunteer
What this study did
NCT03462017 · Sanofi
2018-03-07 – 2018-12-22 · Microvascular Coronary Artery Disease
What this study did
NCT03027674 · Pontificia Universidad Catolica de Chile
2016-08 – 2016-08 · Raynaud Phenomenon Due to Trauma, Raynaud Disease, System; Sclerosis, Lupus Erythematosus, Systemic, Dermatomyositis, Ultrasound Therapy; Complications
What this study did
NCT01514903 · Hanmi Pharmaceutical Company Limited
2011-12 – 2011-12 · Erectile Dysfunction
What this study did
NCT00950404 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-08 – 2009-09 · Healthy Volunteers
What this study did
Phase 4 (9)
Pulmonary Arterial Hypertension
NCT07713914 · University of Sao Paulo General Hospital
2026-07-22 – 2028-12-31 · Pulmonary Arterial Hypertension (PAH)
What this study did
NCT02891850 · Bayer
2017-01-11 – 2020-03-03 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT06064448 · Xintian Pharmaceutical
2019-03-19 – 2022-12-22 · Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Erectile Dysfunction
What this study did
NCT03633565 · Assiut University
2018-09 – 2021-11 · Myopathy
What this study did
NCT03431649 · Dr. Soetomo General Hospital
2017-04-01 – 2017-10-30 · Pediatric Pulmonary Hypertension
What this study did
NCT01122264 · Eli Lilly and Company
2010-05 – 2011-06 · Erectile Dysfunction
What this study did
NCT01153204 · Federal University of São Paulo
— · Erectile Dysfunction
What this study did
NCT00461565 · Bayer
2005-02 – 2006-10 · Safety
What this study did
NCT00655590 · Bayer
2005-01 – 2006-06 · Erectile Dysfunction
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT04179747 · International Islamic University, Islamabad
2018-01-18 – 2018-07-24 · Erectile Dysfunction
What this study did
Appears in other studies (6)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT06954597 · Topadur Pharma AG
2025-02-04 – 2026-10-31 · Digital Ulcers in Systemic Sclerosis
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04898114 · Sohag University
2021-06-02 – 2025-06-01 · Persistent Pulmonary Hypertension of Newborn
What this study did
Phase 4 (4)
Pulmonary Arterial Hypertension
NCT02284737 · Nanjing First Hospital, Nanjing Medical University
2014-11-28 – 2021-07-30 · Pulmonary Arterial Hypertension
What this study did
NCT00617305 · Gilead Sciences
2008-04 – 2011-07 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT06875258 · The Netherlands Cancer Institute
2024-01-15 – 2027-01-01 · Erectile Dysfunction Following Radical Prostatectomy
What this study did
NCT00512707 · Boston University
2006-11 – 2010-05 · Erectile Dysfunction, Testosterone Deficiency, Diabetes
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sildenafil (Revatio): this drugApprovedSmall moleculePDE5Partial signal
NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001).
Ambrisentan (Letairis)ApprovedSmall moleculeEndothelin A receptorReliable signal
NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction
NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001).
Bosentan (Tracleer)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant)
NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults.
Epoprostenol (Flolan)
ApprovedUS marketing discontinued
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Macitentan (Opsumit)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier
Riociguat (Adempas)ApprovedSmall moleculeSoluble guanylate cyclaseReliable signal
NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5)
Sotatercept (Winrevair)ApprovedProtein / enzyme therapeuticActivin receptor type IIA (ActRIIA)Reliable signal
NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5)
NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025).
Tadalafil (Adcirca)ApprovedSmall moleculePDE5Weak signal
NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed
NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks.
Treprostinil (Orenitram)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49)
Treprostinil (Remodulin)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5)
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Weak signalFeatured results are safety only in this race
AR1001
Phase 3(overall)
Small moleculePDE5
Partial signal(overall)
No reviewed efficacy summary in this indication
Extended-Release Tacrolimus (VI-0106)Phase 3Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Imatinib Mesylate Prodrug (IkT-001Pro)Phase 3Small moleculePDGFR (imatinib-class)not yet gradedNo reviewed efficacy summary in this indication
RalinepagPhase 3Small moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001.
SeralutinibPhase 3Small moleculePDGFR/CSF1R/KIT (multi-kinase)Partial signal
NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Udenafil (Zydena)Phase 2/3Small moleculePDE5Weak signalNo reviewed efficacy summary in this indication
APL-9796Phase 2Monoclonal antibodyZIP12 (zinc transporter)not yet gradedNo reviewed efficacy summary in this indication
ROC-101Phase 2Small moleculeRho-associated kinase (ROCK, pan)not yet gradedNo reviewed efficacy summary in this indication
RTN-001
Phase 2(overall)
Small moleculePDE5
not yet graded(overall)
No reviewed efficacy summary in this indication
VasigrobartPhase 2Monoclonal antibodyPDGF-Bnot yet gradedNo reviewed efficacy summary in this indication
ZamicastatPhase 2Small moleculeDBHWeak signalNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
F230
—(overall)
Small moleculeEndothelin A receptornot yet gradedNo reviewed efficacy summary in this indication
GSK6792070
—(overall)
UndisclosedActivin signallingnot yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)Weak signal
NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1)
PF-07868489DiscontinuedProtein / enzyme therapeuticBone morphogenetic protein 9 (BMP9)Partial signalNo reviewed efficacy summary in this indication

Upcoming events

(15 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Revatio (sildenafil) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 4Erectile DysfunctionsRecruiting
Est. primary completion 2026-12 · NCT07391579 · CT.gov ↗
What to watch
Phase 2Spinal Cord Injuries, Urinary IncontinenceActive not recruiting
Est. primary completion 2026-12-01 · NCT04565925 · CT.gov ↗
What to watch
2027 (6)
May 2027 (3)
Phase 2Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2027-05 · NCT05061368 · CT.gov ↗
What to watch
Phase 2HypertensionNot yet recruiting
Est. primary completion 2027-05-02 · NCT07647003 · CT.gov ↗
What to watch
Phase 1Fontan CirculationRecruiting
Est. primary completion 2027-05-31 · NCT06324396 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1Dysmenorrhea, Menstrual Pain, Endometriosis, Uterine FibroidNot yet recruiting
Est. primary completion 2027-06 · NCT07508358 · CT.gov ↗
What to watch
Phase 2Hypoxic-Ischemic EncephalopathyNot yet recruiting
Est. primary completion 2027-06 · NCT06810284 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Traumatic Brain InjuryRecruiting
Est. primary completion 2027-12-31 · NCT05782244 · CT.gov ↗
What to watch
2028 (2)
April 2028 (2)
Phase 2/3Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2028-04 · NCT07824674 · CT.gov ↗
What to watch
Phase 1Brain TumorNot yet recruiting
Est. primary completion 2028-04-30 · NCT07039760 · CT.gov ↗
What to watch
2029 (2)
October 2029 (1)
Phase 4Peyronie DiseaseActive not recruiting
Est. primary completion 2029-10 · NCT06649539 · CT.gov ↗
What to watch
December 2029 (1)
Phase 1Vascular DiseasesRecruiting
Est. primary completion 2029-12 · NCT06510322 · CT.gov ↗
What to watch
2030 (3)
February 2030 (1)
Phase 3Rectal CancerRecruiting
Est. primary completion 2030-02 · NCT06123156 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2/3CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT06800092 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2Neonatal EncephalopathyRecruiting
Est. primary completion 2030-10 · NCT06098833 · CT.gov ↗
What to watch

See the full readout calendar ↗